Harmony's Courtroom Clock Now Ticks Louder Than Its Pipeline

A $269M WAKIX quarter, a fresh orexin dataset, and a February injunction hearing — the keyword cloud rotated from science to litigation, and the stock still trades near $2B against $1.3B of net cash.

HRMY · Earnings Call · 2026-11-04

The quarter the story moved from molecules to a docket

The commercial machine did what it has done for six straight quarters. WAKIX delivered $269 million in net revenue, 400 net patient adds, roughly 9,350 average patients, and management reiterated full-year guidance of $1.00–1.04 billion — the first billion-dollar year in company history. Adam Zaeske framed it as an acceleration, not a maturing brand: 400-plus adds in five of the last six quarters, against only two such quarters in the brand's entire prior history. But the language of the call changed underneath that steady top line. In the June quarter the company's own keyword profile was pure pharmacology — half life sat at the very top, flanked by orexin-2 receptor selectivity and single-ascending-dose mechanics. This quarter the list reorders itself around a different word: preliminary injunction, which has never appeared in Harmony's keyword history before, arrived at the top of the stack alongside a cluster of litigation vocabulary — polymorph patent, amorphous formulation, PI hearing. That is the genuine change. In May, when Jason Gerberry asked about an at-risk generic launch, Peter Anastasiou — then speaking as General Counsel — offered only a gesture: “there are legal remedies that we have access to that we would fully implement” — Peter Anastasiou, General Counsel · 2026-05-07. Yesterday it became a calendar entry.

There is a schedule. Yesterday, the judge issued a scheduling order that there is a scheduled preliminary injunction hearing... The scheduling or the preliminary injunction hearing will take place on the 26th. That then gives her a couple of weeks prior to the stay, the 30-month stay ending in mid-February, and then we expect a decision both on the injunction and the ANDA case.
Peter Anastasiou, President and Chief Operating Officer · 2026-11-04

So the next fifteen months compress into a brutal geometry: a January 26, 2027 PI hearing, a ruling expected by February 14, 2027 as the 30-month stay lapses, an amorphous-form suit that likely will not be tried until 2029, and a pitolisant GR PDUFA on April 1, 2027. Management's entire defense rests on a portfolio argument — three patents, only one of which has to hold.

What quietly left the script

The more interesting omission is not in the transcript but in the emphasis. Pitolisant HD, the high-dose formulation that once ranked as the company's number one and number two keyword, has fallen out of the top tier entirely. So has pediatric exclusivity, which two quarters ago was a headline theme and is now mentioned only as a consequence of the Prader-Willi TEMPO study rather than as a strategic priority in its own right. Yet pediatric exclusivity is precisely what moves generic entry from September 2029 to March 2030 — the entire valuation hinge. The exciting science (orexin) has crowded out the mundane franchise arithmetic (HD, GR, six-month exclusivity) that actually determines cash flows into the 2040s. Interestingly, Harmony is not alone on the Prader-Willi question. Another CNS reporter this week, Neurocrine, was framing Prader Willi patients as a live commercial frontier — a reminder that Harmony's PWS trial is doing double duty: an indication with genuine unmet need, and a regulatory key that unlocks six months of exclusivity on a billion-dollar asset.

The tolerability concession

The BP-205 multiple-ascending-dose data were, on paper, clean: mean Tmax around 60 minutes, mean effective half-life of roughly 29 hours supporting once-daily dosing, headache in about 25% of 94 healthy volunteers, insomnia under 20%, urinary frequency and urgency under 20% and only at the 1mg and 3mg doses, and zero discontinuations. That is what pushed multiple ascending dose into the company's top ten keywords. But listen to what Anastasiou conceded when pressed on whether efficacy could be separated from the on-target side effects: “people should not expect that we will completely avoid those target engagement side effects. They are part and parcel of raising orexin levels.” — Peter Anastasiou, President and Chief Operating Officer · 2026-11-04 That is an honest but meaningful step back from a pure best-in-class claim. The differentiation now rests on magnitude and tolerability of class effects rather than their absence — and Kumar Budur declined to disclose dose-response for insomnia, deferring to a future medical meeting. The next real read is the sleep-deprived healthy volunteer study in Q1 2027, the first efficacy signal for the molecule.

The cheapest cash machine in sleep medicine

Step back and the setup is strange. Harmony carries a $2.0 billion market capitalization against $1.3 billion of effective net cash — an enterprise value near $700 million for a business doing north of $1 billion in annualized revenue. The multiple compression has been relentless: price to revenue of 2.2x against 10.6x at the 2020 peak, with interest coverage of 30.4x and a balance sheet that barely uses leverage. Not all of the erosion is sentiment. The P&L is now paying for its own IP defense and licensing: gross margin slipped 5.2 points year over year to 75.8%, and Steve Mollichella pinned the cause precisely — “Cost of products sold was 30% of net revenue compared to 25% one year ago. This year-over-year increase was primarily driven by a new royalty related to the Novitium license agreement.” — Steve Mollichella, Chief Financial Officer · 2026-11-04 Defending the franchise is no longer free; it shows up in the gross line. The tape agrees with neither the bulls nor the panic. HRMY is down 5.5% over ninety days, 19.7% off its September 2 high of $42.86, and 43.5% below the December 2022 peak of $60.91. The October 12 CEO handoff to Anastasiou — the lawyer who built the IP estate, moving into the operator's chair on January 1 — cost more than 5% in a single session. Investors read the succession as a defensive signal rather than a growth signal, even as management insists it is “a position of strength... continuity, strength, and growth” — Jeffrey Dayno, Chief Executive Officer · 2026-11-04.

What to watch

Three catalysts now sit inside roughly ninety days of each other in early 2027: PI/ANDA rulings in February, the GR PDUFA on April 1, and the first BP-205 efficacy readout in sleep-deprived volunteers. Meanwhile the orexin ambition is widening — Anastasiou described the BD aperture opening toward cognition, attention, mood and fatigue, territory far from the orphan-rare CNS sandbox Harmony has occupied for a decade. Dayno had insisted a year ago that the strategy was “not sort of either/or” — Jeffrey Dayno, Chief Commercial Officer · 2026-05-07, and the new data support that — but the widening scope also raises the capital-allocation stakes for a company that has $1 billion sitting idle while its own shares imply deep scepticism about the franchise it is defending. That is the tension worth carrying forward: a cash-generative commercial asset priced for litigation loss, defended by a new CEO whose principal credential is the very IP strategy now under scrutiny.